NUVL

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.

Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 139.60 USD with a low forecast of 105.00 USD and a high forecast of 158.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nuvalent Inc revenue for the last quarter amounts to -112.70M USD, increased 47.64 % YoY.

Nuvalent Inc. EPS for the last quarter amounts to -70462000.00 USD, increased 53.79 % YoY.

Nuvalent Inc (NUVL) has 142 emplpoyees as of December 17 2025.

Today NUVL has the market capitalization of 7.97B USD.